Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Alternative Splicing
  • Antineoplastic Agents
  • Exons
  • Lung Neoplasms
  • Mutation
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins c-met

abstract

  • Oncogenic mutations in the MET exon 14 splice sites that cause exon 14 skipping occur in 4% of lung adenocarcinomas. We report responses to the MET inhibitors crizotinib and cabozantinib in patients with lung adenocarcinomas harboring MET exon 14 splice site mutations, identifying a new potential therapeutic target in this disease. Cancer Discov; 5(8); 842-9. ©2015 AACR.See related commentary by Ma, p. 802.See related article by Frampton et al., p. 850.This article is highlighted in the In This Issue feature, p. 783.

publication date

  • January 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4658654

Digital Object Identifier (DOI)

  • 10.1158/2159-8290.CD-14-1467

PubMed ID

  • 25971939

Additional Document Info

start page

  • 842

end page

  • 9

volume

  • 5

number

  • 8